

Per Soelberg Srensen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3744973/per-soelberg-sorensen-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

329
papers

25,862
citations

70
h-index

154
g-index

347
ext. papers

30,808
ext. citations

7.3
avg, IF

6.74
L-index

#	Paper	IF	Citations
329	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology, The</i> , 2018 , 17, 162-173	24.1	2419
328	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011 , 476, 214-9	50.4	1948
327	Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , 2014 , 83, 278-86	6.5	1632
326	The relation between inflammation and neurodegeneration in multiple sclerosis brains. <i>Brain</i> , 2009 , 132, 1175-89	11.2	944
325	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013 , 45, 1353-60	36.3	934
324	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet, The</i> , 2001 , 357, 1576-82	40	884
323	The changing demographic pattern of multiple sclerosis epidemiology. <i>Lancet Neurology, The</i> , 2010 , 9, 520-32	24.1	737
322	A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 416-26	59.2	591
321	Remyelination is extensive in a subset of multiple sclerosis patients. <i>Brain</i> , 2006 , 129, 3165-72	11.2	558
320	Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 285, 1316-21	27.4	322
319	Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. <i>Lancet, The</i> , 2003 , 362, 1184-91	40	315
318	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019 , 365,	33.3	309
317	Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. <i>Lancet, The</i> , 2000 , 355, 2189-93	40	308
316	EFNS guidelines on diagnosis and management of neuromyelitis optica. <i>European Journal of Neurology</i> , 2010 , 17, 1019-32	6	292
315	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 96-120	5	286
314	The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 305-17	5	286
313	Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. <i>Acta Neurochirurgica</i> , 1990 , 107, 37-43	3	280

312	Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. <i>Lancet, The</i> , 2000 , 355, 2194-8	40	269
311	Widespread demyelination in the cerebellar cortex in multiple sclerosis. <i>Brain Pathology</i> , 2007 , 17, 38-446		254
310	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. <i>Nature Genetics</i> , 2015 , 47, 717-726	36.3	244
309	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. <i>Lancet Neurology, The</i> , 2011 , 10, 745-58	24.1	212
308	EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. <i>European Journal of Neurology</i> , 2008 , 15, 893-908	6	211
307	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 263-81	5	203
306	Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. <i>European Journal of Neurology</i> , 2005 , 12, 817-27	6	202
305	Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 46, 1163-9	4	201
304	Demyelination versus remyelination in progressive multiple sclerosis. <i>Brain</i> , 2010 , 133, 2983-98	11.2	200
303	Immunogenicity of interferon- β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. <i>Annals of Neurology</i> , 2000 , 48, 706-712	9.4	192
302	Metastatic epidural spinal cord compression. Results of treatment and survival. <i>Cancer</i> , 1990 , 65, 1502-86.4		188
301	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 143-52	5	186
300	Evolving concepts in the treatment of relapsing multiple sclerosis. <i>Lancet, The</i> , 2017 , 389, 1347-1356	40	185
299	Stroke incidence and risk factors for stroke in Copenhagen, Denmark. <i>Stroke</i> , 1988 , 19, 1345-53	6.7	185
298	Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. <i>European Journal of Cancer</i> , 1994 , 30A, 396-8	7.5	184
297	Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. <i>Lancet Neurology, The</i> , 2010 , 9, 740-50	24.1	164
296	Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. <i>Neurology</i> , 2005 , 65, 33-9	6.5	161
295	Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. <i>PLoS ONE</i> , 2013 , 8, e57820	3.7	157

294	Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. <i>Lancet Neurology, The</i> , 2011 , 10, 329-37	24.1	156
293	Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. <i>Lancet, The</i> , 2004 , 364, 1149-56	4.0	153
292	Multiple sclerosis after infectious mononucleosis. <i>Archives of Neurology</i> , 2007 , 64, 72-5		141
291	Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1594-1604	5	140
290	A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. <i>Journal of Neurology</i> , 2014 , 261, 773-83	5.5	136
289	Intracranial pressure and cerebrospinal fluid outflow conductance in healthy subjects. <i>Journal of Neurosurgery</i> , 1991 , 74, 597-600	3.2	126
288	Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. <i>Tissue Antigens</i> , 2004 , 63, 237-47		115
287	Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. <i>Journal of Neurology</i> , 2014 , 261, 1170-7	5.5	107
286	EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. <i>European Journal of Neurology</i> , 2005 , 12, 939-46	6	106
285	Danish very-low-dose aspirin after carotid endarterectomy trial. <i>Stroke</i> , 1988 , 19, 1211-5	6.7	106
284	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. <i>Nature Medicine</i> , 2014 , 20, 272-82	50.5	103
283	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017 , 140, 2776-2796	11.2	102
282	Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. <i>European Journal of Neurology</i> , 2002 , 9, 557-63	6	98
281	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. <i>Annals of Neurology</i> , 2003 , 53, 718-24	9.4	96
280	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 318-31	5	92
279	Simvastatin as add-on therapy to interferon β 1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. <i>Lancet Neurology, The</i> , 2011 , 10, 691-701	24.1	92
278	Cerebrospinal fluid flow and production in patients with normal pressure hydrocephalus studied by MRI. <i>Neuroradiology</i> , 1994 , 36, 210-5	3.2	92
277	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 282-93	5	91

276	Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRibine Tablets treating multiple sclerosis orally) study. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 578-93	5	88
275	IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. <i>Neurology</i> , 2004 , 63, 2028-33	6.5	87
274	Differential microRNA expression in blood in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1849-57	5.7	86
273	NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2009 , 8, 519-29	24.1	85
272	Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients. <i>Acta Medica Scandinavica</i> , 1977 , 201, 207-13		84
271	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1386-1396	5	83
270	Risk factors for acute respiratory tract infections in young Greenlandic children. <i>American Journal of Epidemiology</i> , 2003 , 158, 374-84	3.8	81
269	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1533-8	5	79
268	The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. <i>Therapeutic Advances in Neurological Disorders</i> , 2016 , 9, 44-52	6.6	77
267	The six spot step test: a new measurement for walking ability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 495-500	5	77
266	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 342-9	5	76
265	New management algorithms in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2014 , 27, 246-59	7.1	75
264	Cerebral blood flow in patients with normal-pressure hydrocephalus before and after shunting. <i>Journal of Neurosurgery</i> , 1987 , 66, 379-87	3.2	75
263	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , 2019 , 18, 185-197	24.1	74
262	Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 431-6	5	74
261	Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. <i>International Journal of Cancer</i> , 1999 , 81, 357-65	7.5	74
260	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018 , 175, 1679-1687	16.7	72
259	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19. <i>Journal of Medical Internet Research</i> , 2020 , 22, e19992	7.6	70

258	Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. <i>European Journal of Neurology</i> , 2009 , 16, 420-3	6	68
257	Motor disturbances in normal-pressure hydrocephalus. Special reference to stance and gait. <i>Archives of Neurology</i> , 1986 , 43, 34-8		68
256	Cognitive impairment in newly diagnosed multiple sclerosis patients: a 4-year follow-up study. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 77-85	3.2	67
255	A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. <i>Genes and Immunity</i> , 2002 , 3, 279-85	4.4	67
254	Sexual dysfunction in male and female patients with epilepsy: a study of 86 outpatients. <i>Archives of Sexual Behavior</i> , 1990 , 19, 1-14	3.5	66
253	A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. <i>Cephalalgia</i> , 1986 , 6, 7-14	6.1	64
252	Intracerebral haemorrhage after carotid endarterectomy. <i>European Journal of Vascular Surgery</i> , 1987 , 1, 51-60		64
251	Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 219-28	5	63
250	CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 877-84	5	62
249	Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. <i>Lancet Neurology</i> , 2010 , 9, 672-80	24.1	62
248	Association between an interleukin-13 promoter polymorphism and atopy. <i>International Journal of Immunogenetics</i> , 2003 , 30, 355-9		60
247	Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 622-30	5	59
246	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 590-603	5	58
245	Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2012 , 9, 215	10.1	58
244	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 294-304	5	57
243	Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. <i>Neurology</i> , 2006 , 67, 1681-3	6.5	57
242	Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?. <i>Journal of the Neurological Sciences</i> , 2011 , 311, 58-63	3.2	55
241	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 29, 168-174	4	54

240	Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 32-42	5	54
239	Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. <i>Archives of Neurology</i> , 2006 , 63, 533-6		53
238	The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 235-42	5	52
237	Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. <i>European Journal of Neurology</i> , 1996 , 3, 23-28	6	52
236	Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. <i>Headache</i> , 1991 , 31, 650-7	4.2	52
235	Reproduction and the risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1604-9	5	51
234	Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. <i>Journal of Neuroimmunology</i> , 2009 , 212, 125-31	3.5	51
233	Clinical course and prognosis of pseudotumor cerebri. A prospective study of 24 patients. <i>Acta Neurologica Scandinavica</i> , 1988 , 77, 164-72	3.8	50
232	Population-based study of acute respiratory infections in children, Greenland. <i>Emerging Infectious Diseases</i> , 2002 , 8, 586-93	10.2	49
231	Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). <i>Multiple Sclerosis Journal</i> , 2002 , 8, 295-8	5	49
230	Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 169-173	4	48
229	CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006 , 181, 157-64	3.5	48
228	Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1723-9	5	47
227	Safety concerns and risk management of multiple sclerosis therapies. <i>Acta Neurologica Scandinavica</i> , 2017 , 136, 168-186	3.8	47
226	Resistance to cerebrospinal fluid outflow and intracranial pressure in patients with hydrocephalus after subarachnoid haemorrhage. <i>Acta Neurochirurgica</i> , 1987 , 88, 79-86	3	47
225	Prevalence of stroke in a district of Copenhagen the copenhagen city heart study. <i>Acta Neurologica Scandinavica</i> , 1982 , 66, 68-81	3.8	46
224	Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. <i>Immunology</i> , 2009 , 128, e451-61	7.8	46
223	Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. <i>European Journal of Neurology</i> , 2009 , 16, 1291-8	6	46

222	Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 247-52	5	46
221	Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. <i>Journal of Neurology</i> , 2007 , 254, 827-37	5.5	45
220	Endocrine studies in patients with pseudotumor cerebri. Estrogen levels in blood and cerebrospinal fluid. <i>Archives of Neurology</i> , 1986 , 43, 902-6		45
219	Assessment of CSF dynamics and venous flow in the superior sagittal sinus by MRI in idiopathic intracranial hypertension: a preliminary study. <i>Neuroradiology</i> , 1994 , 36, 350-4	3.2	44
218	Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e47578	3.7	42
217	Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 1074-8	5	42
216	Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 33, 595-8	4	42
215	High cerebrospinal fluid concentration of glial fibrillary acidic protein (GFAP) in patients with normal pressure hydrocephalus. <i>Journal of the Neurological Sciences</i> , 1985 , 70, 269-74	3.2	42
214	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. <i>Trials</i> , 2019 , 20, 263	2.8	41
213	The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. <i>Genes and Immunity</i> , 2001 , 2, 263-8	4.4	41
212	Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. <i>Journal of the Neurological Sciences</i> , 2005 , 233, 61-5	3.2	39
211	MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). <i>Multiple Sclerosis Journal</i> , 2005 , 11, 433-40	5	39
210	Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. <i>European Journal of Clinical Investigation</i> , 1984 , 14, 435-9	4.6	39
209	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756285617753365	6.6	38
208	Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. <i>European Journal of Neurology</i> , 2007 , 14, 850-9	6	38
207	Cerebrospinal fluid vasopressin and increased intracranial pressure. <i>Annals of Neurology</i> , 1984 , 15, 435-40	4	37
206	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 627-636	5	37
205	Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. <i>Neurology</i> , 2017 , 89, 1668-1675	6.5	35

204	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 577-87	5	35
203	Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 559-66	5	35
202	Disease protection and interleukin-10 induction by endogenous interferon- β in multiple sclerosis?. <i>European Journal of Neurology</i> , 2011 , 18, 266-272	6	35
201	Comorbidity in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 851	4.1	35
200	Pulsed immune reconstitution therapy in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419836913	6.6	34
199	Long-term prognosis after transient ischemic attacks. <i>Acta Neurologica Scandinavica</i> , 1981 , 63, 156-68	3.8	34
198	Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. <i>Clinical Therapeutics</i> , 2007 , 29, 1128-45	3.5	34
197	Studies of vasopressin in the human cerebrospinal fluid. <i>Acta Neurologica Scandinavica</i> , 1986 , 74, 81-102	3.8	34
196	A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 234-241	5	33
195	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. <i>Journal of Neurology</i> , 2013 , 260, 1136-46	5.5	33
194	Health-related quality of life in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 386-92	5	33
193	CSF-amine metabolites in depression, dementia and in controls. <i>Acta Psychiatrica Scandinavica</i> , 1987 , 75, 619-28	6.5	33
192	Multiple sclerosis impairs regional functional connectivity in the cerebellum. <i>NeuroImage: Clinical</i> , 2014 , 4, 130-8	5.3	32
191	Gene expression analysis of interferon-beta treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 615-21	5	32
190	Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. <i>Journal of Neurology</i> , 2016 , 263, 2484-2493	5.5	32
189	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. <i>Neurological Sciences</i> , 2020 , 41, 1647-1650	3.5	31
188	Visual evoked potentials in pseudotumor cerebri. <i>Archives of Neurology</i> , 1985 , 42, 150-3		31
187	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 819-827	5	31

186	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 332-41 ⁵		30
185	High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 675-685	5	30
184	Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 39-46	5	30
183	Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. <i>PLoS ONE</i> , 2016 , 11, e0162752	3.7	30
182	The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis. <i>Current Opinion in Neurology</i> , 2019 , 32, 320-326	7.1	30
181	Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2012 , 126, 421-7	3.8	29
180	Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 616-21	5	29
179	Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. <i>Acta Neurochirurgica</i> , 1987 , 86, 93-7	3	29
178	Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study. <i>Neurology</i> , 2020 , 95, e1041-e1051	6.5	28
177	Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 942-9	5	28
176	Persistent disturbances of cognitive functions in patients with pseudotumor cerebri. <i>Acta Neurologica Scandinavica</i> , 1986 , 73, 264-8	3.8	28
175	Vasopressin in the cerebrospinal fluid of patients with normal pressure hydrocephalus and benign intracranial hypertension. <i>European Journal of Endocrinology</i> , 1982 , 100, 211-5	6.5	28
174	Long-term prognosis and quality of life after reversible cerebral ischemic attacks. <i>Acta Neurologica Scandinavica</i> , 1989 , 79, 204-13	3.8	27
173	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017 , 12, e0170395	3.7	27
172	The Danish Multiple Sclerosis Treatment Register. <i>Clinical Epidemiology</i> , 2016 , 8, 549-552	5.9	27
171	Progressive multiple sclerosis, cognitive function, and quality of life. <i>Brain and Behavior</i> , 2018 , 8, e00875 ^{3,4}		26
170	Cytokine profiles show heterogeneity of interferon- γ response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e202	9.1	26
169	FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2012 , 170, 149-55	6.2	26

168	Resting-state connectivity of pre-motor cortex reflects disability in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013 , 128, 328-35	3.8	26
167	Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 253-64	5	26
166	The role of intravenous immunoglobulin in the treatment of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2003 , 206, 123-30	3.2	26
165	Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q. <i>Genes and Immunity</i> , 2000 , 1, 456-9	4.4	26
164	Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 1986 , 4, 1620-7	2.2	26
163	Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. <i>CNS Drugs</i> , 2020 , 34, 269-280	6.7	25
162	Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1444-1451	5	25
161	Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1841-8	5	25
160	Neutralizing antibodies against interferon-Beta. <i>Therapeutic Advances in Neurological Disorders</i> , 2008 , 1, 125-41	6.6	25
159	Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. <i>Scandinavian Journal of Immunology</i> , 2006 , 64, 155-63	3.4	25
158	Do concentrations of neurotransmitters measured in lumbar cerebrospinal fluid reflect the concentrations at brain level?. <i>Acta Neurochirurgica</i> , 1988 , 91, 55-9	3	25
157	Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 81-4	5	24
156	Correlations of brain MRI parameters to disability in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2001 , 104, 24-30	3.8	24
155	Severe headache as the only symptom of long-standing shunt dysfunction in hydrocephalic children with normal or slit ventricles revealed by computed tomography. <i>Childs Nervous System</i> , 1985 , 1, 49-52	1.7	24
154	Minocycline added to subcutaneous interferon β 1a in multiple sclerosis: randomized RECYCLINE study. <i>European Journal of Neurology</i> , 2016 , 23, 861-70	6	24
153	The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 601-5	5	23
152	Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 5-8	5	23
151	Low cerebrospinal fluid concentration of brain-specific protein D2 in patients with normal pressure hydrocephalus. <i>Journal of the Neurological Sciences</i> , 1983 , 62, 59-65	3.2	23

150	Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 179-87	5	22
149	Defining active progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1727-1735	5	22
148	Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis. <i>Magnetic Resonance in Medicine</i> , 2005 , 53, 750-9	4.4	22
147	Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. <i>Archives of Neurology</i> , 2005 , 62, 1519-30		22
146	Comparison of myelography combined with postmyelographic spinal CT and MRI in suspected metastatic disease of the spinal canal. <i>Journal of Neuro-Oncology</i> , 1992 , 13, 231-7	4.8	22
145	Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration. <i>European Journal of Clinical Pharmacology</i> , 1984 , 26, 719-22	2.8	22
144	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020 , 143, 2637-2652	11.2	22
143	Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study. <i>Neurology</i> , 2019 , 92, e1811-e1820	6.5	21
142	Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. <i>Multiple Sclerosis and Related Disorders</i> , 2012 , 1, 49-54	4	21
141	Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. <i>Neurology</i> , 2004 , 63, S42-9	6.5	21
140	Worsening of disability caused by relapses in multiple sclerosis: A different approach. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 32, 1-8	4	20
139	Prediction of response to interferon therapy in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014 , 130, 268-75	3.8	20
138	Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon- β . <i>European Journal of Neurology</i> , 2009 , 16, 43-7	6	20
137	Principles of a new treatment algorithm in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 351-62	4.3	20
136	Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 837-42	5	20
135	Essential tremor treated with propranolol: lack of correlation between clinical effect and plasma propranolol levels. <i>Annals of Neurology</i> , 1981 , 9, 53-7	9.4	20
134	Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 926-34	5	19
133	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. <i>Neuron</i> , 2016 , 92, 333-335	13.9	19

132	Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis. <i>Genes and Immunity</i> , 2010 , 11, 142-54	4.4	19
131	Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 305-13	5	19
130	Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. <i>Neurological Research</i> , 2005 , 27, 591-7	2.7	19
129	Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 944-54	5	19
128	Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 323-8	5	18
127	Prediction of antibody persistency from antibody titres to natalizumab. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1493-9	5	18
126	Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1298-1305	5	17
125	Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1414-22	5	17
124	Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1226-9	5	17
123	Radiologic features compared to clinical findings in a prospective study of 153 patients with metastatic spinal cord compression treated by radiotherapy. <i>Acta Neurochirurgica</i> , 1997 , 139, 105-11	3	17
122	Fatal neurogenic pulmonary edema in a patient with progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 711-5	5	17
121	IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. <i>Experimental Brain Research</i> , 2007 , 178, 462-3 ³	5	17
120	Significantly increased fractions of transformed to total alpha2-macroglobulin concentrations in plasma from patients with multiple sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2004 , 1690, 203-7	6.9	17
119	Association between age at onset of multiple sclerosis and vitamin D level-related factors. <i>Neurology</i> , 2016 , 86, 88-93	6.5	16
118	Physical and social environment and the risk of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 600-6	4	16
117	Cognitive deficits in multiple sclerosis: correlations with T2 changes in normal appearing brain tissue. <i>Acta Neurologica Scandinavica</i> , 2012 , 125, 338-44	3.8	16
116	Gender and autoimmune comorbidity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1244-51	5	16
115	Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships. <i>European Journal of Neurology</i> , 2017 , 24, 825-834	6	15

114	Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity. <i>PLoS ONE</i> , 2014 , 9, e95540	3.7	15
113	Prevalence of mitral valve prolapse in younger patients with cerebral ischaemic attacks. A blinded controlled study. <i>Acta Medica Scandinavica</i> , 1984 , 216, 385-91		15
112	Cerebrospinal fluid vasopressin as a marker of central nervous system metastases from small-cell bronchogenic carcinoma. <i>Journal of Clinical Oncology</i> , 1985 , 3, 48-53	2.2	15
111	The window of opportunity for treatment of progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2020 , 33, 262-270	7.1	14
110	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369	5	14
109	Endogenous interferon- β -inducible gene expression and interferon- β -treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis. <i>PLoS ONE</i> , 2015 , 10, e0118830	3.7	14
108	Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1557-65	5	14
107	Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011 , 311 Suppl 1, S29-34	3.2	14
106	The incidence and clinical presentation of neurosyphilis in Greater Copenhagen 1974 through 1978. <i>Acta Neurologica Scandinavica</i> , 1981 , 63, 237-46	3.8	14
105	The relationship between MRI and PET changes and cognitive disturbances in MS. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 99-102	3.2	14
104	Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2003 , 143, 101-6	3.5	14
103	CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 641-5	5	14
102	No linkage or association of the nitric oxide synthase genes to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2001 , 119, 95-100	3.5	14
101	Correlates of heterosexual behavior among 23-87 year olds in Denmark and Sweden, 1992-1998. <i>Archives of Sexual Behavior</i> , 2000 , 29, 91-106	3.5	14
100	Vasopressin release during electroconvulsive therapy. <i>Psychoneuroendocrinology</i> , 1982 , 7, 303-8	5	14
99	Correlation between anti-interferon- β -binding and neutralizing antibodies in interferon- β -treated multiple sclerosis patients. <i>European Journal of Neurology</i> , 2012 , 19, 1311-7	6	13
98	The SH2D2A gene and susceptibility to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008 , 197, 152-83.5		13
97	Intravenous polyclonal human immunoglobulins in multiple sclerosis. <i>Neurodegenerative Diseases</i> , 2008 , 5, 8-15	2.3	13

96	Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. <i>International Journal of MS Care</i> , 2017 , 19, 16-24	2.3	13
95	Early safety and efficacy of fingolimod treatment in Denmark. <i>Acta Neurologica Scandinavica</i> , 2017 , 135, 129-133	3.8	12
94	Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 181-186	4	12
93	Neutralizing antibodies against interferon- β do not predispose antibodies against natalizumab. <i>Neurology</i> , 2011 , 76, 759-60	6.5	12
92	The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. <i>Clinical Immunology</i> , 2008 , 129, 80-9	9	12
91	Multiple sclerosis: pathophysiology revisited. <i>Lancet Neurology</i> , 2005 , 4, 9-10	24.1	12
90	Gender effects on treatment response to interferon-beta in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014 , 130, 374-9	3.8	11
89	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. <i>Neuroscience Letters</i> , 2012 , 530, 155-60	3.3	11
88	Endogenous and recombinant type I interferons and disease activity in multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e35927	3.7	11
87	Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study. <i>Neurological Research</i> , 2012 , 34, 52-8	2.7	11
86	Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents. <i>CNS Drugs</i> , 2017 , 31, 357-371	6.7	10
85	Expert opinion on the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420935019	6.6	10
84	Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. <i>Journal of Immunological Methods</i> , 2016 , 430, 1-9	2.5	10
83	Cerebrospinal fluid and plasma vasopressin during short-time induced intracranial hypertension. <i>Acta Neurochirurgica</i> , 1985 , 77, 46-51	3	10
82	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1543-1555	5	10
81	Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. <i>Neurology and Therapy</i> , 2020 , 9, 55-66	4.6	9
80	Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study. <i>Clinical Drug Investigation</i> , 2012 , 32, 15-27	3.2	9
79	Electroconvulsive therapy: a comparison of seizure duration as monitored with electroencephalograph and electromyograph. <i>Acta Psychiatrica Scandinavica</i> , 1981 , 64, 193-8	6.5	9

78	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. <i>Lancet Neurology, The</i> , 2021 , 20, 917-929 ^{24.1}	9
77	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019 , 326, 19-27	3.5 9
76	Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. <i>Journal of Neurology</i> , 2019 , 266, 306-315	5.5 9
75	Ozanimod: a better or just another S1P receptor modulator?. <i>Lancet Neurology, The</i> , 2016 , 15, 345-7	24.1 8
74	Prognostic value of in vitro measurements of platelet aggregability and fibrinolytic activity in patients with reversible cerebral ischemic attacks. <i>European Neurology</i> , 1983 , 22, 437-41	2.1 8
73	24-hour cerebrospinal fluid levels of vasopressin in hydrocephalic patients. <i>Regulatory Peptides</i> , 1985 , 10, 115-26	8
72	Antibodies to IFN-beta: the Danish National IFN-beta Project. <i>Neurology</i> , 2003 , 61, S27-8	6.5 8
71	Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 67-74	5.5 8
70	Therapeutic interference with leukocyte recirculation in multiple sclerosis. <i>European Journal of Neurology</i> , 2015 , 22, 434-42	6 7
69	Employment, disability pension and income for children with parental multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1148-1156	5 7
68	Tolfenamic acid versus propranolol in the prophylactic treatment of migraine. <i>Acta Neurologica Scandinavica</i> , 1994 , 89, 446-50	3.8 7
67	A case of malignant lymphoma and myasthenia gravis. <i>Scandinavian Journal of Haematology</i> , 1983 , 31, 155-60	7
66	Bone lesions in early syphilis detected by bone scintigraphy. <i>Sexually Transmitted Infections</i> , 1984 , 60, 265-8	2.8 7
65	Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017 , 136, 330-337	3.8 6
64	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595	5 6
63	Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 40, 101956	4 6
62	Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 912-4	5.5 6
61	Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014 , 276, 195-201	3.5 6

60	Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis. <i>Neurological Research</i> , 2014 , 36, 701-8	2.7	6
59	The chemokine receptor CCR5 B2 allele in natalizumab-treated multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014 , 129, 27-31	3.8	6
58	Effects of fingolimod in relapsing-remitting multiple sclerosis. <i>Lancet Neurology</i> , 2014 , 13, 526-7	24.1	6
57	Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. <i>European Journal of Human Genetics</i> , 2011 , 19, 1100-3	5.3	6
56	Oral fumarate for relapsing-remitting multiple sclerosis. <i>Lancet</i> , 2008 , 372, 1447-8	40	6
55	Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2007 , 69, 1552; author reply 1553	6.5	6
54	Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 1996 , 1, 349-52	5	6
53	Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study. <i>Journal of Neurology</i> , 2016 , 263, 2229-2237	5.5	6
52	Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?. <i>Nature Reviews Neurology</i> , 2016 , 12, 5-6	15	5
51	Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 188-197	5	4
50	Disability in progressive MS is associated with T2 lesion changes. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 20, 73-77	4	4
49	Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study). <i>Multiple Sclerosis and Related Disorders</i> , 2013 , 2, 141-6		4
48	Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 1309-17	4.3	4
47	Ophthalmologic prognosis in benign intracranial hypertension. <i>Acta Ophthalmologica</i> , 1985 , 173, 62-4	3.7	4
46	REGARD: what can we learn from randomised, open-label, head-to-head studies?. <i>Lancet Neurology</i> , 2008 , 7, 864-6	24.1	4
45	The gap between effect of drugs and effectiveness of treatments. <i>Journal of the Neurological Sciences</i> , 2007 , 259, 128-32	3.2	4
44	Intravenous immunoglobulin treatment in neurologic disorders: yes. <i>Archives of Neurology</i> , 1999 , 56, 1025-7		4
43	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19 (Preprint)		4

42	Predictors of treatment outcome in patients with paediatric onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 964-975	5	4
41	Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 556-562	5.5	4
40	Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NO. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1260-3	5	3
39	Cladribine in the treatment of multiple sclerosis. <i>Clinical Investigation</i> , 2011 , 1, 317-326		3
38	Linkage analysis suggests a region of importance for multiple sclerosis in 3p14-13. <i>Genes and Immunity</i> , 2001 , 2, 451-4	4.4	3
37	Prophylactic Effect of Flunarizine versus Metoprolol in Migraine. <i>Cephalalgia</i> , 1989 , 9, 355-356	6.1	3
36	Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 37, 101431	4	3
35	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. <i>Frontiers in Neurology</i> , 2021 , 12, 647811	4.1	3
34	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103012	4	3
33	Cardiac disease in patients with reversible cerebral ischemic events. <i>Acta Medica Scandinavica</i> , 1985 , 217, 417-21		2
32	Comparison of clinical neurological function and CT response during chemotherapy for initial brain metastases from small cell lung cancer. <i>Acta Neurologica Scandinavica</i> , 1994 , 89, 372-7	3.8	2
31	Can we spot the IFNbeta nonresponders?. <i>Neurology</i> , 2008 , 71, 1936-7	6.5	2
30	A prospective PET study of patients with glioblastoma multiforme. <i>Acta Neurologica Scandinavica</i> , 2006 , 113, 412-8	3.8	2
29	Neutralising antibodies against interferon beta in multiple sclerosis. <i>Lancet, The</i> , 2004 , 363, 168-169	4.0	2
28	Central motor conduction as a measure of disease progression in early multiple sclerosis. <i>European Journal of Neurology</i> , 1995 , 1, 233-41	6	2
27	Carotid artery disease and low cerebral perfusion pressure: symptomatology, operative risk and outcome. <i>Neurological Research</i> , 1990 , 12, 35-40	2.7	2
26	Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder. <i>Pattern Recognition</i> , 2022 , 123, 108403	7.7	2
25	Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 50, 102813	4	2

24	Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
23	Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 54, 103107	4	2
22	Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. <i>Journal of International Medical Research</i> , 2008 , 36, 204-8; author reply 208-10	1.4	2
21	Segmenting Multiple Sclerosis Lesions Using a Spatially Constrained K-Nearest Neighbour Approach. <i>Lecture Notes in Computer Science</i> , 2012 , 156-163	0.9	1
20	Plasma vasopressin, cortisol, and growth hormone concentrations in relation to surgery in the suprasellar region. <i>Acta Medica Scandinavica</i> , 1984 , 216, 31-9		1
19	How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?. <i>European Journal of Neurology</i> , 2009 , 16, 287-8	6	1
18	Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided). <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1070-2	5	1
17	A new millennium? perhaps. A new european journal of Neurology? certainly!. <i>European Journal of Neurology</i> , 2000 , 7, 1	6	1
16	Elektromyografisk monitorering ved narko-curare-elektrostimulation. <i>Nordic Journal of Psychiatry</i> , 1979 , 33, 9-14		1
15	Treatment of hookworm anemia. <i>Scandinavian Journal of Infectious Diseases</i> , 1971 , 3, 65-9		1
14	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211058298	6.6	1
13	Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon- β <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 39, 101894	4	1
12	039 Rates of lymphopenia in years 1-4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A16.2-A16	5.5	1
11	Relapses add to permanent disability in relapsing multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103029	4	1
10	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068	5	1
9	Neutralising antibodies to interferon- β measurement, clinical relevance, and management. <i>Journal of Neurology</i> , 2006 , 253, vi16-vi22	5.5	0
8	Population Pharmacokinetic-BECell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis.. <i>CNS Drugs</i> , 2022 , 36, 283	6.7	0
7	Disease-modifying treatments for relapsing-remitting multiple sclerosis 2013 , 64-87		

- 6 Neutralizing antibodies directed against biologic agents to treat multiple sclerosis 287-299
- 5 Intravenous immunoglobulin to treat multiple sclerosis 444-453
- 4 Resource allocation to brain research in Europe. *European Journal of Neurology*, **2007**, 14, 597 6
- 3 A follow-up study of Nordic multiple sclerosis candidate gene regions. *Multiple Sclerosis Journal*, **2007**, 13, 584-9 5
- 2 Early-stage multiple sclerosis : what are the treatment options?. *Drugs*, **2004**, 64, 2021-9 12.1
- 1 The Effect on MRI of Gammaglobulin Treatment in Relapsing Multiple Sclerosis. *Multiple Sclerosis Journal*, **2000**, 6, S14-S17 5